“The Race Against a Silent Killer” World health organization report on Hypertension: 2023
Keywords:
Hypertension, Global burden, Cardiovascular diseases, Public healthAbstract
The World Health Organization's Global Report on Hypertension: The Race Against a Silent Killer provides a comprehensive analysis of the global burden of hypertension. The report highlights that hypertension affects one in three adults worldwide, with the number of individuals living with the condition doubling from 650 million in 1990 to 1.3 billion in 2019. Alarmingly, approximately 46% of adults with hypertension are unaware of their condition, and about 80% are not receiving adequate treatment. The report underscores the significant health risks associated with uncontrolled hypertension, including heart attacks, strokes, kidney damage, and premature death. It also emphasizes the economic impact, noting substantial losses for communities and countries. The report advocates for the implementation of effective hypertension management strategies, such as the WHO HEARTS technical package, and highlights the potential to prevent 76 million deaths between 2023 and 2050 through improved treatment coverage.
How to cite this article:
Thappar H, Singh H, Saini N. “The Race Against
a Silent Killer” World health organization report
on Hypertension: 2023. Rec Adv Path Lab Med.
2024;10(1&2):7-10.
DOI: https://doi.org/10.24321/2454.8642.202403
References
World Health Organization. Global Report on Hypertension 2023. Geneva: WHO; 2023.
World Health Organization. Hypertension: Silent killer, global public health crisis. Geneva: WHO; 2023.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and treatment from 1990 to 2019: A pooled analysis of population-based studies. Lancet. 2023;401(10395):123-133.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2022;360(9344):123-133.[Google Scholar]
World Health Organization. Noncommunicable Diseases Progress Monitor 2023. Geneva: WHO; 2023.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2023;289(19):2560-72.[Google Scholar]
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and trends from 1990 to 2023: A systematic analysis. Lancet. 2023;388(10053):1073-1090.[Google Scholar]
World Health Organization. WHO Global NCD Action Plan 2013–2023. Geneva: WHO; 2023.
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2022;16(4):223-237.[Google Scholar]
Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802 [Google Scholar]
World Health Organization. Sodium Intake for Adults and Children: Guideline. Geneva: WHO; 2023.
Campbell NRC, Lackland DT, Niebylski ML, Orias M, Redburn KA. Population dietary sodium reduction: The state of the science. J Clin Hypertens. 2023;15(11):801-805.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Recent Advances in Pathology and Laboratory Medicine ( ISSN: 2454-8642 )
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
